What is the significance of the new revolving credit agreement?

The new $4.0 billion revolving credit agreement significantly enhances Amgen's financial flexibility. It provides a substantial liquidity backstop for its commercial paper program and general corporate needs, ensuring ample funds are available for operations and strategic initiatives. The ability to potentially increase the facility further adds to its strategic value.

Why did Amgen terminate its large bridge credit facility?

Amgen terminated the $28.5 billion bridge credit facility because it has secured sufficient liquidity from other sources to fund its acquisition of Horizon Therapeutics plc. These sources include proceeds from recent senior note issuances, a term loan facility, and existing cash reserves, making the bridge facility no longer necessary.

How does this impact Amgen's financing for the Horizon Therapeutics acquisition?

The termination of the bridge facility, coupled with the existing financing arrangements (senior notes, term loan, cash), confirms that Amgen has adequate funds in place to complete the Horizon Therapeutics acquisition. This move indicates efficient capital management and a clear path forward for the acquisition without the need for the more expensive bridge financing.

What are the interest rate and fees associated with the new revolving credit agreement?

Interest rates are variable, tied to either the Adjusted Term SOFR Rate (or EURIBOR for Euro advances) plus a margin between 0.68% and 1.10%, or a base rate plus a margin between 0.00% and 0.10%. The specific margin depends on Amgen's senior long-term unsecured debt rating. Amgen will also pay an annual fee for committed funds, ranging from 0.07% to 0.15%, depending on its credit rating.

AMGN 8-K: Material Agreements

Summary

Amgen Inc. (AMGN) has announced a significant amendment and restatement of its revolving credit facility, increasing its total commitment to $4.0 billion. This facility, with an initial five-year term extendable by two additional one-year periods, is designed for general corporate purposes and serves as a liquidity backstop for its commercial paper program. The credit agreement includes provisions for an additional $1.25 billion increase at Amgen's request, subject to bank discretion and customary requirements. This strategic move enhances Amgen's financial flexibility and provides robust liquidity to support its operations and potential future needs. Furthermore, Amgen has fully terminated its previously established $28.5 billion bridge credit facility. This termination, effective March 9, 2023, follows the successful securing of substantial financing through senior notes, a term loan facility, and existing cash reserves. The company has determined that these combined liquidity sources are sufficient to finance the completion of its acquisition of Horizon Therapeutics plc, rendering the bridge facility unnecessary. The termination signifies a prudent management of its debt structure and a clear pathway to funding its strategic growth initiatives.

Key Highlights

1Amgen has entered into a Third Amended and Restated Revolving Credit Agreement with a total commitment of $4.0 billion.
2The new credit facility has an initial term of five years, with potential extensions for up to two additional one-year periods.
3There is a provision to increase the credit facility by up to an additional $1.25 billion at Amgen's request, subject to bank discretion.
4The revolving credit facility will serve as a liquidity backstop for Amgen's commercial paper program and for general corporate purposes.
5Amgen has elected to terminate its $28.5 billion bridge credit facility in its entirety.
6The termination of the bridge facility is due to sufficient liquidity from senior notes, term loan facility, and cash on hand to fund the Horizon Therapeutics acquisition.
7The termination of the bridge facility streamlines Amgen's financing structure and reduces associated fees.

AMGEN INC 8-K Report, Material Agreement (Mar 9, 2023)

Summary

Key Highlights

Frequently Asked Questions